NRX Pharmaceuticals, Inc.
NRXP Nasdaq
SEC CIK 1719406
Follow NRX Pharmaceuticals
Weekly email: filings, results
Revenue, last quarter
$1.2M
+378.9% vs same quarter last year
Net income
−$2.2M
+63.1% vs same quarter last year
EPS, diluted
−$0.05
+81.5% vs same quarter last year
Operating cash flow
−$6.7M
−132% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $1.2M | −$28.6M |
| FY24 | $0 | −$25.1M |
| FY23 | $0 | −$30.2M |
| FY22 | - | −$39.8M |
| FY21 | - | −$93.1M |
| FY20 | - | −$51.8M |
| FY19 | - | $408.4K |
| FY18 | - | $66.1K |
| FY17 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | - |
| FY24 | −$10.6M |
| FY23 | −$21.7M |
| FY22 | −$39.8M |
| FY21 | −$37.7M |
| FY20 | −$2.3M |
| FY19 | - |
| FY18 | - |
| FY17 | - |